Monopar Therapeutics Form 4 insider transactions

Monopar Therapeutics CEO Chandler Robinson reported the vesting of restricted stock units and associated tax-related share dispositions, increasing direct common stock holdings.

Tactic Pharma LLC, a 10% owner, sold 550,229 shares of Monopar Therapeutics common stock for $63.6098 per share, reducing its beneficial ownership.

Monopar Therapeutics director Kim R. Tsuchimoto sold 8,904 shares of common stock for approximately $356,000 after exercising stock options at a nominal price.

Monopar Therapeutics Director Christopher M. Starr exercised stock options and subsequently sold 16,800 shares of common stock for approximately $672,000.

Monopar Therapeutics CEO and Director Chandler Robinson exercised stock options and subsequently sold 16,800 shares of common stock for approximately $40.00 per share.

Monopar Therapeutics CEO and Director Chandler Robinson reported the vesting of 13,344 restricted stock units and the subsequent disposition of 5,865 shares for tax withholding, alongside an indirect beneficial ownership of 822,255 shares.

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, increased his direct beneficial ownership of common stock to 45,858 shares following the vesting of restricted stock units on June 30, 2025.

Tactic Pharma LLC, a 10% owner of Monopar Therapeutics, disposed of 33,334 shares of common stock at a weighted average price of $35 on April 2, 2025, reducing its holdings to 822,255 shares.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Chandler Robinson, CEO of Monopar Therapeutics, reports the vesting and settlement of restricted stock units, resulting in the acquisition and disposal of common stock.

Chandler Robinson, CEO of Monopar Therapeutics, reports acquisition and disposal of common stock and derivative securities related to vesting of restricted stock units and stock options.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition of stock options and restricted stock units in a recent SEC filing.

Christopher M. Starr, a director at Monopar Therapeutics, acquired stock options exercisable for 11,365 shares of common stock on March 4, 2025.

Director Arthur Klausner reports acquisition of stock options in Monopar Therapeutics.

Director Raymond Anderson acquired 11,365 stock options in Monopar Therapeutics on March 4, 2025.

Director Lavina Talukdar reports the acquisition of stock options in Monopar Therapeutics.

Director Kim R. Tsuchimoto reports the acquisition of stock options in Monopar Therapeutics.

Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics, was granted 25,000 stock options on March 3, 2025, according to a Form 4 filing.

Patrice Rioux, Acting Chief Medical Officer of Monopar Therapeutics, was granted 2,000 stock options on January 1, 2025.

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, acquired 1,790 shares of common stock and disposed of 721 shares to cover taxes related to vesting restricted stock units on December 31, 2024.

Monopar Therapeutics CEO Chandler Robinson acquired shares through the vesting of restricted stock units, while also having shares withheld for tax purposes.

TacticGem LLC distributed 1,433,334 shares of Monopar Therapeutics common stock to its affiliates, Gem Pharmaceuticals, LLC and Tactic Pharma, LLC, without consideration.

Karthik Radhakrishnan, CFO of Monopar Therapeutics, reports the acquisition of 1,550 shares of common stock at a price of $16.25 per share on October 28, 2024.

Chandler Robinson, CEO of Monopar Therapeutics, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.

Andrew Cittadine, COO of Monopar Therapeutics, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.

Karthik Radhakrishnan, CFO of Monopar Therapeutics, was granted 125,000 stock options on July 1, 2024, according to a Form 4 filing.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.

Kim R. Tsuchimoto, CFO of Monopar Therapeutics, reports the acquisition and disposal of common stock related to the vesting of restricted stock units.

Chandler Robinson, CEO of Monopar Therapeutics, reports the acquisition of shares through vesting of restricted stock units and the withholding of shares for tax obligations.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reported purchasing shares of the company's common stock in two transactions.